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Purpose: To investigate the role of postoperative topical 0.05% cyclosporine A (CsA) eye 
drops (Restasis®, Allergan Pharmaceutical) in the prevention of recurrence among patients with 
primary pterygium treated with bare-sclera technique.
Methods: In this prospective randomized controlled study, 36 eyes (34 patients) with primary 
pterygium were randomized into two groups: Group I comprised 18 eyes (18 patients), and 
Group II comprised 18 eyes (16 patients). Bare sclera technique was performed in both groups. 
In Group I, 0.05% CsA was administered postoperatively at 6-hour intervals for 6 months, and 
Group II did not receive any cyclosporine treatment. The patients were assessed for recurrence, 
side effects, and complications at postoperative 1 and 7 days as well as each month during 
the following year. Conjunctival advances which showed a limbus higher than 1 mm were 
recognized as recurrence.
Results: Recurrence occurred in four patients (22.2%) in Group I and in eight (44.4%) patients 
in Group II.
Conclusion: Postoperative application of low-dose CsA can be effective for preventing recur-
rences after primary pterygium surgery.
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Introduction
Pterygium is a common ocular surface disease characterized by tissue remodeling, 
cellular proliferation, neovascularization, and inflammation.1,2 A stromal overgrowth 
of fibroblast and blood vessels are accompanied by an inflammatory cell infiltrate and 
abnormal extracellular matrix accumulation.3–6 Although several hypotheses have been 
associated with its etiology, its pathology still remains to be explained. Secretion of 
proinflammatory cytokines such as interleukin (IL)-1, IL-6, IL-8, and tumor necrosis 
factor (TNF)-α secondary to chronic ultraviolet (UV) radiation, is a widely recog-
nized etiological factor in pathogenesis of this lesion.6,7 These cytokines can stimulate 
proliferation of cultured Tenon’s capsule fibroblasts and induce expression of matrix 
metalloproteinases in cultured pterygium; specifically, IL-1 plays an important role 
in the development process of pterygium.6,7
The vascular endothelial growth factor (VEGF) family, which is known to have a 
role in angiogenesis, has been shown to exhibit an increase in pterygium epithelium 
and vascular endothelium.8–13 VEGF is believed to be stimulated by a mediation of 
TNF-α through UVB (ultraviolet B) induction.14
Cyclosporine A (CsA) shows a selective effect against T-helper cells and prevents 
the synthesis and secretion of ILs.16 CsA has also been shown to block angiogenic Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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factors induced by VEGF.15–17 Based on these studies, we 
thought CsA might have an effective role on treatment of 
pterygium.
The aim of this study was to investigate the influence of 
postoperative topical CsA use on recurrence.
Method
This study was a prospective randomized controlled study on 
36 consecutive eyes of primary pterygium. Written informed 
consent was obtained from all the patients. All pterygia were 
located nasally. Ocular diseases and surgical history of the 
patients are shown in Table 1. The patients were random-
ized into two groups: 18 eyes of 18 patients were included 
in Group I, and 18 eyes of 16 patients were included in 
Group II. Female/male ratio was the same in both groups 
(nine female, nine male).
The inclusion criteria were:
•	 Diagnosis of primary pterygium
•	 Pterygium size $2 mm (the horizontal length of the 
tissue from limbus to cornea was measured by slit lamp 
biomicroscopy)
•	 Ocular discomfort refractory to medical treatment
•	 Visual loss induced by pterygium.
Patients who had a recurrent pterygium or allergy to 
topical CsA, and those who were pregnant, were excluded 
from the study.
Bare sclera method was performed in both groups. 
  Surgical procedures were performed under local anesthesia 
using an operation microscope. The pterygium head was taken 
off the cornea by blunt dissection with a crescent knife. The 
body of pterygium was dissected and excised with Westcott 
scissors. Minimal cautery was used to maintain hemostasis. 
The conjunctiva was closed together with a size 8/0 vicryl 
suture, leaving a 4-mm bare sclera. The eyes were closed 
with a rondel after the application of antibiotic ointment. In 
all of the patients, antibiotic drops were given for 15 days 
and steroid drops were given for 1 month. In Group I, 0.05% 
CsA (Restasis®, Allergan Pharmaceutical) was administered 
postoperatively at 6-hour intervals for 6 months. In Group II, 
patients did not receive CsA. All patients were followed 
up at postoperative 1 day, 7 days, and then every month. 
Minimum duration of the follow-up periods was 12 months. 
In each follow-up, patients were assessed for recurrence 
and postoperative complications such as persistent corneal 
defect, infection, scleral melting, and drop intolerance. The 
recurrence was defined as fibrovascular tissue invading the 
cornea $1 mm).17,18
statistical analyses
NCSS (Number Cruncher Statistical System) 2007 and PASS 
(Power Analysis and Sample Size) 2008 statistical software 
(NCSS, Kaysville, UT) was used for the statistical analyses. 
The study data were expressed by definitive statistics (mean, 
standard deviation, median). Quantitative data were compared 
by independent samples t-test and Mann–Whitney U test. The 
Table 1 Ocular diseases and surgical history of the patients
Disease/surgery Number of cases (n = 34)
glaucoma 10
Diabetic retinopathy 6
Trabeculectomy 6
Vitreoretinal surgery 9
implantation of Ahmed glaucoma valve 1
Scleral fixation intraocular lens 2
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Figure 2 Distribution of the recurrence-free follow-up times.
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relationship between the pterygium size and the recurrence 
time was evaluated by Spearman’s rank correlation analysis. 
Recurrence-free survival time was evaluated by Kaplan–
Meier survival analysis. Categorical data were evaluated 
by Chi-square test. P , 0.05 was recognized as statistically 
significant.
Results
Our study was performed on 36 eyes in total (18 eyes in 
Group I and 18 eyes in Group II). None of the groups dem-
onstrated scleral thinning, necrosis, or any other visually 
significant complication. The CsA group (Group I) showed 
no adverse reaction other than a mild burning sensation 
and irritation at the time of the application. There was no 
statistically significant difference between the groups with 
regard to age (P . 0.05). Mean age was 57.05 ± 11.65 in 
Group I and 53.27 ± 10.88 in Group II. No statistically 
significant difference was determined between the groups 
in terms of pterygium size (P . 0.05). Mean pterygium 
size was 3.00 ± 0.57 mm in Group I and 2.73 ± 0.61 mm in 
Group II. We observed no statistically significant difference 
between the recurrence times of the groups (P . 0.05). Mean 
recurrence time was 2.62 ± 0.95 months in Group I and 
1.87 ± 0.83 months in Group II. There was no statistically 
significant difference between the groups relative to gender 
distribution (P . 0.05). Although recurrence rate was higher 
in Group II than in Group I, the difference was not statistically 
significant (P . 0.05) Table 2. No statistically significant dif-
ference was determined between the cases with and without 
recurrence in terms of pterygium size (P . 0.05) Table 3.
In view of all cases with recurrence, although pterygium 
size and recurrence time showed a considerable positive 
correlation, it was not statistically significant (r = 0.343; 
P . 0.05) Table 4. In Group I, pterygium size and recurrence 
displayed a negative correlation in four cases with recurrence; 
however, due to the low number of cases, it was not found to 
be statistically significant (P . 0.05). In Group II, pterygium 
size and recurrence showed a significant positive correla-
tion (68.4%) in eight cases with recurrence (pterygium size 
elevated parallel to the increases in recurrence time).
In Group I, while four cases exhibited recurrence 
Figure 1, 14 (77.8%) did not show recurrence, and the mean 
recurrence-free follow-up time was 9.92 ± 0.92 months. 
In Group II, while eight cases exhibited recurrence, 10 
(55.6%) cases did not show recurrence, and the mean 
recurrence-free follow-up time was 7.50 ± 1.19 months 
Table 5. Recurrence-free survival rates were evaluated by 
logrank test and no statistically significant difference was 
determined between the 12-month survival rates (P = 0.130, 
P . 0.05) Figure 2. 
Discussion
Previously, pterygium was recognized as a degenera-
tive condition; recently, as a result of the latest studies, 
it is thought to be a growth disorder, and mainly pro-
liferative factors are investigated for revealing the true 
etiopathogenesis.5,17 Therefore, surgical treatments aim 
to replace limbal stem cells, whereas adjuvant therapies 
target preventing proliferation and angiogenesis. Despite 
those studies, a definitive treatment method which shows 
no recurrence, along with the least degree of complica-
tions, has yet to be found. The most widely recognized 
proposal for pathogenesis is that UV increases release 
of certain multifactorial cytokines, IL-6 and IL-8, from 
pterygium epithelium, which leads to the initialization of 
Table 2 evaluations relative to the groups
Group I Group II Pa
Mean ± SD Mean ± SD
Age (year) 57.05 ± 11.65 53.27 ± 10.88 0.322
Pterygium size  
(mm)
3.00 ± 0.57 2.73 ± 0.61 0.169
recurrence time  
(months)c
2.62 ± 0.95 1.87 ± 0.83 0.213
n (%) n (%) Pb
gender Female 9 (50.0) 9 (50.0) 1.000
Male 9 (50.0) 9 (50.0)
recurrence Yes 4 (22.2) 8 (44.4) 0.157
no 14 (77.8) 10 (55.6)
Notes: aindependent samples t-test; bChi-square test; cMann–Whitney U test.
Abbreviation: sD, standard deviation.
Table 3 evaluation of the pterygium sizes relative to recurrence 
rates
Recurrence Pterygium size (mm) P
n Mean ± SD Median
(+) 12 2.73 ± 0.61 2.55
0.305
(-) 24 2.93 ± 0.59 2.90
Note: independent samples t-test was applied.
Table 4 The relationship between the pterygium size and the 
recurrence time
Pterygium size  
(mm)
Recurrence time   
(months)
ra P
group i (n = 4) -0.632 0.368
group ii (n = 8) 0.684 0.013b
Total (n = 12) 0.343 0.276
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neovascularization and chronic inflammation.5–7 IL-6 has 
been shown to increase   angiogenesis via VEGF induction.19 
Despite considerable contribution of UV and environmental 
factors, occurrence of pterygium is varied in people living 
in the same   environment. Hypersensitivity is a powerful 
factor in pathogenesis, and the amount of immunoglobu-
lin E (IgE) has been found to exhibit an elevated level in 
pterygium tissue.19 IgE rise leads to release of cytokines, 
causing thrombocyte aggregation, which causes release of 
growth factors leading to epithelium proliferation. Although 
previous studies demonstrate that T lymphocytes are rarely 
identified in conjunctiva, they are found to be in elevated 
levels in pterygium tissue.19 All those data show the impor-
tance of T-lymphocyte-mediated strong cellular immunity 
in pterygium pathogenesis. CsA selectively suppresses 
functions of T-helper lymphocytes and production of both 
inflammatory cytokines and inflammatory mediators.20,21 In 
animal studies, it has been shown to suppress IgE production 
in a T-cell-dependent manner and inhibit histamine release 
from basophil and mast cells.21 In vivo and in vitro studies 
have showed that CsA inhibits angiogenesis triggered by 
VEGF. We believed that inhibiting all those paths with CsA, 
which are thought to have a role over pterygium pathogen-
esis, might be effective in preventing recurrence.22 CsA 
0.05% is found to be effective in inhibiting the proliferation 
in Tenon’s capsule fibroblasts.23 In a study similar to ours, 
thiotepa and cyclosporine have been compared following 
pterygium surgery and CsA was found to be significantly 
more effective than thiotepa.24
The recurrence rate was 44.4% for bare sclera technique 
and 22.2% for bare sclera technique + topical 0.05% CsA. 
None of our cases demonstrated a serious complication. 
Moreover, recurrence rate was observed to decrease. Our 
study group was comprised of glaucoma or diabetic retin-
opathy patients who had a history of vitreoretinal or glau-
coma surgery in whom we could not perform a treatment 
with conjunctival or limbal autograft. Therefore, we were 
unable to deliver mitomycin and other adjuvant therapies 
and thus had the chance to evaluate efficacy of CsA in a 
surgical procedure associated with high recurrence rates. 
Because of this study design, we believe that our study 
obtained more reliable results on the effects of CsA over 
recurrence rates.
Similar studies have been performed by using   conjunctival 
autografts. Tok et al used CsA following primary excision in pri-
mary pterygium cases, and the recurrence rate was determined 
to be 12.9%.25 In a study by Aydin et al, CsA was found to be 
effective in reducing recurrence and preventing postoperative 
pain and complications.26 However, Aydin et al used CsA after 
applying limbal conjunctival autograft and observed a recurrence 
rate of 3.4%. Ibáñez et al preferred to apply the combination of 
mitomycin + conjunctival autograft and determined a recurrence 
rate of 7.5%.27 In our study, the recurrence rate was 22.2%.
While our study appears to be similar with that of Tok et al 
our recurrence rate is higher. We believe that by applying 
more effective surgical techniques, such as   conjunctival 
autograft and limbal autograft, we could have obtained bet-
ter results. Moreover, although a remarkable decrease was 
observed in the recurrence rate of the patient group, the 
results were not statistically significant due to the low number 
of cases. However, since it is known to be a safe method, it 
can be performed among patients with a history of major 
surgery or in candidates of such surgeries. In conclusion, we 
believe that more effective results can be achieved by using 
topical CsA at higher doses.
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